Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Emily Peck, National Correspondent at Axios, explains why office vacancies hit 21% despite RTO pushes, highlighting a lasting shift in how Americans work.
Tobias Bauer, CEO & President of Rolling Stock at Siemens Mobility North America, shares insights on a $220M investment reshaping U.S. rail infrastructure.
Kory Kantenga from LinkedIn unpacks how the US added nearly 3x the expected jobs in March, and whether it can last as the Iran war reshapes the economy.
U.S. Air Force pilot Tyler Lucas beat 199 competitors on Beast Games Season 2 to win $5.1M. He joins us live to share how discipline and loyalty won the game.
Osier founder Cheree Ashley spent a decade building recovery programs & now she's channeling that mission into skincare with Selling Sunset's Sandra Vergara.
Genesis just committed to 22 new vehicles by 2030. The brand's COO joins us live to break down their luxury takeover, NY Auto Show reveals, and what's next.
